Phase III Randomized Trial of Maintenance Taxanes Versus Surveillance in Women With Advanced Ovarian/Tubal/Peritoneal Cancer: A Gynecologic Oncology Group 0212:NRG Oncology Study
In the world of maintenance, Taxanes don’t add survival benefits.
Olaparib With or Without Cediranib Versus Platinum-Based Chemotherapy in Recurrent Platinum-Sensitive Ovarian Cancer (NRG-GY004): A Randomized, Open-Label, Phase III Trial
Author(s): Joyce F. Liu, MD1; Mark F. Brady, PhD2; Ursula A. Matulonis, MD1; Austin Miller, PhD2; Elise C. Kohn, MD3; Elizabeth M. Swisher, MD4; David Cella, PhD5; William P. Tew, MD6; Noelle G. Cloven, MD7; Carolyn Y. Muller, MD8; David P. Bender, MD9; Richard G. Moore, MD10; David P. Michelin, MD11; Steven E. Waggoner, MD12; Melissa A. Geller, MD13; Keiichi Fujiwara, MD14; Stacy D. D’Andre, MD15; Michael Carney, MD16; Angeles Alvarez Secord, MD17; Katherine M. Moxley, MD18; and Michael A. Bookman, MD19
Source: DOI: 10.1200/JCO.21.02011 Journal of Clinical Oncology 40, no. 19 (July 01, 2022) 2138-2147.
The study was designed to evaluate the possibility of avoiding chemotherapy in the setting of platinum-sensitive relapsed ovarian cancer. However, chemotherapy was superior to Olaparib/cediranib and Olaparib alone. In addition, cost and duration of therapy of Olaparib-based therapy are likely more and longer respectively as compared to chemotherapy.
PURPOSE
Platinum-based chemotherapy is the standard of care for platinum-sensitive ovarian cancer, but complications from repeated platinum therapy occur. We assessed the activity of two all-oral nonplatinum alternatives, olaparib or olaparib/cediranib, versus platinum-based chemotherapy.
PATIENTS AND METHODS
NRG-GY004 is an open-label, randomized, phase III trial conducted in the United States and Canada. Eligible patients had high-grade serous or endometrioid platinum-sensitive ovarian cancer. Patients were randomly assigned 1:1:1 to platinum-based chemotherapy, olaparib, or olaparib/cediranib. The primary end point was progression-free survival (PFS) in the intention-to-treat population. Secondary end points included activity within germline BRCA-mutated or wild-type subgroups and patient-reported outcomes (PROs).
RESULTS
Between February 04, 2016, and November 13, 2017, 565 eligible patients were randomly assigned. Median PFS was 10.3 (95% CI, 8.7 to 11.2), 8.2 (95% CI, 6.6 to 8.7), and 10.4 (95% CI, 8.5 to 12.5) months with chemotherapy, olaparib, and olaparib/cediranib, respectively. Olaparib/cediranib did not improve PFS versus chemotherapy (hazard ratio [HR] 0.86; 95% CI, 0.66 to 1.10; P = .077). In women with germline BRCA mutation, the PFS HR versus chemotherapy was 0.55 (95% CI, 0.32 to 0.94) for olaparib/cediranib and 0.63 (95% CI, 0.37 to 1.07) for olaparib. In women without a germline BRCA mutation, the PFS HR versus chemotherapy was 0.97 (95% CI, 0.73 to 1.30) for olaparib/cediranib and 1.41 (95% CI, 1.07 to 1.86) for olaparib. Hematologic adverse events occurred more commonly with chemotherapy; however, nonhematologic adverse events were higher with olaparib/cediranib. In 489 patients evaluable for PROs, patients receiving olaparib/cediranib scored on average 1.1 points worse on the NFOSI-DRS-P subscale (97.5% CI, –2.0 to –0.2, P = .0063) versus chemotherapy; no difference between olaparib and chemotherapy was observed.
CONCLUSION
Combination olaparib/cediranib did not improve PFS compared with chemotherapy and resulted in reduced PROs. Notably, in patients with a germline BRCA mutation, both olaparib and olaparib/cediranib had significant clinical activity.
Author Affiliations
1Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 2NRG Oncology; Clinical Trial Development Division; Biostatistics & Bioinformatics; Roswell Park Comprehensive Cancer Center, Buffalo, NY 3Gynecologic Cancer Therapeutics, National Cancer Institute, Rockville, MD 4Gynecologic Oncology, University of Washington, Seattle, WA 5Department of Medical Social Sciences, Northwestern University Health System, Chicago, IL 6Medical Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 7Texas Oncology, Fort Worth Cancer Center, Fort Worth, TX 8Gynecologic Oncology, University of New Mexico, Albuquerque, NM 9Obstetrics and Gynecology, University of Iowa Hospitals and Clinics, Iowa City, IA 10Obstetrics and Gynecology, Wilmot Cancer Institute, University of Rochester, Rochester, NY 11Gynecologic Oncology, Cancer Research Consortium of West Michigan, Munson Medical Center, Traverse City, MI 12Gynecologic Oncology, Cleveland Clinic Health System, Cleveland, OH 13Ob/Gyn & Women’s Health, University of Minnesota, Minneapolis, MN 14Gynecologic Oncology, Saitama Medical University International Medical Center; Hidaka-Shi, Japan 15Executive Chair, Sutter Cancer Research Consortium, Sutter Health Research Enterprise, Sacramento, CA 16Kapialoni Medical Center for Women & Children, University of Hawaii, Honolulu, HI 17Gynecologic Oncology, Duke University Medical Center, Durham, NC 18Stephenson Cancer Center Gynecologic Cancers Clinic, University of Oklahoma Health Sciences Center, Oklahoma City, OK 19Director, Gynecologic Oncology Therapeutics, Kaiser Permanente Northern California, San Francisco, CARelated Articles
A Randomized, Phase III Trial to Evaluate Rucaparib Monotherapy as Maintenance Treatment in Patients With Newly Diagnosed Ovarian Cancer (ATHENA–MONO/GOG-3020/ENGOT-ov45)
Seems like maintenance month, I believe we are all practicing this, but confirmation of the benefit of maintenance PARP inhibitors in ovarian ca even in those without HRD.
OVARIO phase II trial of combination niraparib plus bevacizumab maintenance therapy in advanced ovarian cancer following first-line platinum-based chemotherapy with bevacizumab
FCS hematologist and medical oncologist Gail Wright, MD, FACP, FCCP co-authored a recent phase II study assessing the safety and efficacy of niraparib + bevacizumab as a first-line maintenance therapy for patients with newly diagnosed advanced ovarian cancer. The promising results found the majority to be progression-free in the first 18 months.
Fuzuloparib Maintenance Therapy in Patients With Platinum-Sensitive, Recurrent Ovarian Carcinoma (FZOCUS-2): A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Trial
Another PARP-inhibitor in this setting with reasonable toxicity profile and flexibility of efficacy for patients with mutated or non-mutated BRCA status. More options of therapy may decrease cost of treatment in a competitive market.
Cancer Risks Associated With BRCA1 and BRCA2 Pathogenic Variants
The importance of germline mutation assessment with the support of genetic counselors cannot be overestimated in daily practice. The impact can be very significant. Interesting to see the significantly elevated relative risk for GI cancers (pancreas, gastric) with BRCA 1 and 2 pathogenic variants.
